InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Acumen Pharmaceuticals, Inc.

ABOS Clue Score27
United States Fiscal year ends December CIK 0001576885
$2.02 -5.61% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.02 −85.00% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 1 Jul 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2020Operating income−7.9Net income−7.3Fiscal year 2021Operating income−19.6Net income−100.6EPS, diluted−5.02Fiscal year 2022Operating income−45.2Net income−42.9EPS, diluted−1.06Fiscal year 2023Operating income−61.1Net income−52.4EPS, diluted−1.08Fiscal year 2024Operating income−114.0Net income−102.3EPS, diluted−1.71Fiscal year 2025Operating income−123.8Net income−121.3EPS, diluted−2.00
FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −7.9 −19.6 −45.2 −61.1 −114.0 −123.8
Net income −7.3 −100.6 −42.9 −52.4 −102.3 −121.3
Growth
EPS, diluted n/a −5.02 −1.06 −1.08 −1.71 −2.00

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−7.5Fiscal year 2021Operating cash flow−18.0Capital expenditure−0.0Free cash flow−18.0Fiscal year 2022Operating cash flow−35.2Capital expenditure−0.2Free cash flow−35.3Fiscal year 2023Operating cash flow−43.1Capital expenditure−0.0Free cash flow−43.1Fiscal year 2024Operating cash flow−86.2Capital expenditure−0.0Free cash flow−86.2Fiscal year 2025Operating cash flow−115.5Capital expenditure−0.1Free cash flow−115.6
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −7.5 −18.0 −35.2 −43.1 −86.2 −115.5
Capital expenditure n/a −0.0 −0.2 −0.0 −0.0 −0.1
Free cash flow n/a −18.0 −35.3 −43.1 −86.2 −115.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash43.8Shareholders’ equity−18.6Fiscal year 2021Cash122.2Shareholders’ equity225.2Fiscal year 2022Cash130.1Total debt0.0Net cash (debt)130.1Shareholders’ equity188.8Debt to equity0.00Fiscal year 2023Cash66.9Total debt29.9Net cash (debt)37.0Shareholders’ equity267.0Debt to equity0.11Fiscal year 2024Cash35.6Total debt29.4Net cash (debt)6.2Shareholders’ equity181.8Debt to equity0.16Fiscal year 2025Cash54.0Total debt22.4Net cash (debt)31.6Shareholders’ equity70.4Debt to equity0.32
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 43.8 122.2 130.1 66.9 35.6 54.0
Total debt n/a n/a 0.0 29.9 29.4 22.4
Net cash (debt) n/a n/a 130.1 37.0 6.2 31.6
Shareholders’ equity −18.6 225.2 188.8 267.0 181.8 70.4
Debt to equity n/a n/a 0.00 0.11 0.16 0.32

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
8.0 12.3 32.4 42.3 93.8 104.9
1.4 7.3 12.9 18.8 20.2 18.9
−7.9 −19.6 −45.2 −61.1 −114.0 −123.8
Growth
0.0 0.0 0.0 0.0 0.0 0.0
−7.3 −100.6 −42.9 −52.4 −102.3 −121.3
Growth
Per share
n/a −5.02 −1.06 −1.08 −1.71 −2.00
n/a −5.02 −1.06 −1.08 −1.71 −2.00
Growth
n/a 20.1 40.6 48.6 60.0 60.6
n/a 20.1 40.6 48.6 60.0 60.6
Growth +102.4% +19.7% +23.5% +0.9%

† The diluted share count jumps at 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.